Postoperative depression
Conditions
Interventions
Methylene blue group:Following the completion of anesthesia induction, the intervention was initiated under double-blind conditions. Patients received an intravenous infusion of 2 mg/kg methylene blue
Control group:Following the completion of anesthesia induction, the intervention was initiated under double-blind conditions. Patients received an intravenous infusion of an equal volume (50 ml) of 5%
Sponsors
Chengdu Qingbaijiang District People's Hospital
Eligibility
Sex/Gender
Female
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1. Elective laparoscopic total hysterectomy under general anesthesia; 2. Age 18–65 years; 3. BMI 18–30 kg/m^2; 4. ASA classification I or II; 5. No use of systemic hormonal drugs in the past 2 weeks; 6. Signed informed consent form; 7. Preoperative HAM-D score < 8; 8. Surgical indications are benign uterine diseases (such as uterine fibroids, adenomyosis, abnormal uterine bleeding, endometriosis, uterine prolapse, etc.).
Exclusion criteria
Exclusion criteria: 1. Preoperative diagnosis of dementia, depression, or other severe psychiatric or neurological disorders; 2. A clear history of mental disorders or long-term use of antipsychotics or antidepressants; 3. Known glucose-6-phosphate dehydrogenase (G6PD) deficiency (favism) or allergy to methylene blue; 4. History of drug or alcohol abuse; 5. Use of monoamine oxidase inhibitors, selective serotonin reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors, or other drugs that may induce serotonin syndrome within 2 weeks prior to surgery; 6. Presence of severe systemic diseases affecting heart, lung, liver, or kidney function (e.g., NYHA class III-IV heart failure, severe COPD, Child-Pugh class C liver function, renal failure requiring dialysis); 7. Visual, auditory, or speech impairments that prevent completion of scale assessments; 8. Preoperative MMSE score: illiterate MMSE 6 years of education): MMSE <24 points; 9. Pregnant or breastfeeding women; 10. History of thyroid dysfunction with poor control; 11. Participation in other clinical trials within the past 3 months.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Hamilton Depression Scale score; | — |
Secondary
| Measure | Time frame |
|---|---|
| Concentration of interleukin-1 ß in serum;Concentration of interleukin-6 in serum;Concentration of tumor necrosis factor alpha in serum; | — |
Countries
China
Contacts
Public ContactXUTAO
Chengdu Qingbaijiang District People's Hospital
Outcome results
None listed